Insider Selling: Athira Pharma (NASDAQ:ATHA) CEO Sells $17,791.68 in Stock

Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton sold 2,586 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $6.88, for a total transaction of $17,791.68. Following the sale, the chief executive officer owned 40,828 shares of the company’s stock, valued at $280,896.64. The trade was a 5.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Athira Pharma Stock Up 5.5%

ATHA stock opened at $7.33 on Thursday. Athira Pharma, Inc. has a twelve month low of $2.20 and a twelve month high of $8.36. The company has a market cap of $28.88 million, a P/E ratio of -0.76 and a beta of 2.79. The business’s fifty day moving average is $5.15 and its 200-day moving average is $4.31.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.51). Research analysts anticipate that Athira Pharma, Inc. will post -2.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ATHA has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research note on Wednesday, October 8th. Mizuho set a $4.00 target price on shares of Athira Pharma in a report on Friday, September 19th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Athira Pharma currently has an average rating of “Sell” and a consensus price target of $4.00.

Institutional Trading of Athira Pharma

An institutional investor recently raised its position in Athira Pharma stock. BML Capital Management LLC grew its stake in Athira Pharma, Inc. (NASDAQ:ATHA) by 0.9% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,230,667 shares of the company’s stock after buying an additional 30,000 shares during the quarter. Athira Pharma accounts for about 0.7% of BML Capital Management LLC’s investment portfolio, making the stock its 17th biggest holding. BML Capital Management LLC owned about 8.27% of Athira Pharma worth $976,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.